GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Other Gross PPE

Belite Bio (Belite Bio) Other Gross PPE : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Belite Bio Other Gross PPE?

Belite Bio's Other Gross PPE for the quarter that ended in Mar. 2024 was $0.00 Mil.

Belite Bio's quarterly Other Gross PPE increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($1.42 Mil) but then declined from Dec. 2023 ($1.42 Mil) to Mar. 2024 ($0.00 Mil).

Belite Bio's annual Other Gross PPE increased from Dec. 2021 ($0.14 Mil) to Dec. 2022 ($1.38 Mil) and increased from Dec. 2022 ($1.38 Mil) to Dec. 2023 ($1.42 Mil).


Belite Bio Other Gross PPE Historical Data

The historical data trend for Belite Bio's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio Other Gross PPE Chart

Belite Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Other Gross PPE
0.09 0.14 1.38 1.42

Belite Bio Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 1.42 -

Belite Bio Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Belite Bio (Belite Bio) Business Description

Traded in Other Exchanges
Address
12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.